Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189890 | 0.95 | OPRD1 (0.62) | OPRD1 | |
| SCHEMBL26619347 | 0.95 | OPRD1 (0.62) | OPRD1 | |
| SCHEMBL13479297 | 0.86 | HRH3 (0.47) | OPRD1SPHK2SPHK1LTA4H | |
| SCHEMBL13343774 | 0.85 | ALDH1A1 (0.56) | OPRD1SPHK2SPHK1LTA4H | |
| SCHEMBL1242282 | 0.85 | HDAC8 (0.44) | OPRD1SPHK2SPHK1LTA4H | |
| SCHEMBL1242280 | 0.85 | HDAC8 (0.44) | OPRD1SPHK2SPHK1LTA4H | |
| SCHEMBL12891094 | 0.82 | HDAC8 (0.43) | OPRD1SPHK2SPHK1LTA4H | |
| SCHEMBL24317918 | 0.82 | OPRD1 (0.61) | OPRD1LTA4H | |
| SCHEMBL26619452 | 0.82 | OPRD1 (0.58) | OPRD1LTA4H | |
| SCHEMBL11990426 | 0.82 | MAPK1 (0.54) | OPRD1SPHK2SPHK1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| CN-101917981-B | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2012-11-14 | — | — | CN | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| CN-101917981-A | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2010-12-15 | — | — | CN | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | OPRD1 4021/4885SPHK2 1785/4885SPHK1 1816/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | OPRD1 3296/4885SPHK2 1895/4885SPHK1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.